HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: These data provide additional evidence that vorinostat, which is approved for cutaneous T cell lymphoma and functions as an inhibitor of histone deacetylase (HDAC), can increase the F508del protein pool available for subsequent rescue to the plasma membrane [29].